Drug intelligence / Profile preview

imatinib + acetaminophen

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination of imatinib and acetaminophen**, used together rather than as a single fixed-dose formulation. **Imatinib** is an oral small molecule tyrosine kinase inhibitor primarily targeting BCR-ABL, c-KIT, and PDGFR kinases, and is used to treat **chronic myelogenous leukemia (CML)**, gastrointestinal stromal tumors (GIST), and some other cancers. **Acetaminophen** (paracetamol) is a widely used small molecule analgesic and antipyretic. When combined, there are significant pharmacokinetic drug–drug interactions: imatinib increases acetaminophen plasma levels due to inhibition of acetaminophen glucuronidation. Experimental and clinical data suggest that chronic acetaminophen therapy should be avoided in patients on imatinib because of increased toxicity risk, though limited human data show single-dose co-administration may not require dose adjustment and is generally tolerated[2][4][5][1].

Brand names
Gleevec + TylenolGlivec + Tylenol (and all generic combinations)
Other names
imatinib mesylate + paracetamol
02

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)ABL1 myristoyl pocketPDGFR (PDGFR family)

Beyond the preview

Go deeper on imatinib + acetaminophen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on imatinib + acetaminophen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call